Researchers explored the antitumoral potential of the humanized huCD20-Fc-AFN in 5 different humanized patient-derived xenograft (PDX) models of huCD20+ aggressive B non-Hodgkin lymphomas.
[Experimental Hematology & Oncology]
High Efficacy of huCD20-Targeted AcTaferon in Humanized Patient Derived Xenograft Models of Aggressive B Cell Lymphoma
